G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts
{"title":"2016年临床研究:专题文章","authors":"G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts","doi":"10.1016/j.eii.2017.03.002","DOIUrl":null,"url":null,"abstract":"<div><p>Many high quality articles were published in 2016 regarding Crohn's disease (CD) and ulcerative colitis (UC). The importance of diet and microbes in inflammatory bowel disease (IBD), the burden of IBD on patient quality of life are some of the relevant topics. The role of calprotectin or the possibility of using PET for follow-up is also highlighted.</p><p>IBD treatment has been the focus of numerous clinical trials, which have consolidated infliximab (suggesting levels in week 2), adalimumab, and golimumab as front-line treatment. The use of ustekinumab in CD is supported, with methotrexate being left as a last resort, except in the case of arthropathy. Other treatments investigated that are worth mentioning were stem cells, other biosimilar, and new drugs.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"16 3","pages":"Pages 106-113"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2017.03.002","citationCount":"0","resultStr":"{\"title\":\"Investigación clínica en 2016: artículos destacados\",\"authors\":\"G. Trejo, A. Marco-Marqués, S.V. Hernández, M.M. Boscá-Watts\",\"doi\":\"10.1016/j.eii.2017.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Many high quality articles were published in 2016 regarding Crohn's disease (CD) and ulcerative colitis (UC). The importance of diet and microbes in inflammatory bowel disease (IBD), the burden of IBD on patient quality of life are some of the relevant topics. The role of calprotectin or the possibility of using PET for follow-up is also highlighted.</p><p>IBD treatment has been the focus of numerous clinical trials, which have consolidated infliximab (suggesting levels in week 2), adalimumab, and golimumab as front-line treatment. The use of ustekinumab in CD is supported, with methotrexate being left as a last resort, except in the case of arthropathy. Other treatments investigated that are worth mentioning were stem cells, other biosimilar, and new drugs.</p></div>\",\"PeriodicalId\":100473,\"journal\":{\"name\":\"Enfermedad Inflamatoria Intestinal al Día\",\"volume\":\"16 3\",\"pages\":\"Pages 106-113\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.eii.2017.03.002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Enfermedad Inflamatoria Intestinal al Día\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1696780117300210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedad Inflamatoria Intestinal al Día","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1696780117300210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Investigación clínica en 2016: artículos destacados
Many high quality articles were published in 2016 regarding Crohn's disease (CD) and ulcerative colitis (UC). The importance of diet and microbes in inflammatory bowel disease (IBD), the burden of IBD on patient quality of life are some of the relevant topics. The role of calprotectin or the possibility of using PET for follow-up is also highlighted.
IBD treatment has been the focus of numerous clinical trials, which have consolidated infliximab (suggesting levels in week 2), adalimumab, and golimumab as front-line treatment. The use of ustekinumab in CD is supported, with methotrexate being left as a last resort, except in the case of arthropathy. Other treatments investigated that are worth mentioning were stem cells, other biosimilar, and new drugs.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
